Chronic actinic dermatitis (CAD) is a persistent eczematous photodermatosis that usually affects elderly people.1 Numerous therapeutic approaches have been tried for CAD; however, only psoralen–UV-A (PUVA) desensitization, cyclosporine, azathioprine, and/or a combination of them have consistently been successful.2-4 Mycophenolate mofetil is an immunosuppressant that has been used primarily to prevent rejection in patients who have undergone renal transplantation.5 Because of its similar efficacy and safer profile, mycophenolate has been used as an attractive alternative to azathioprine in the treatment of immunologically mediated diseases.6 We describe 2 patients with CAD who successfully responded to PUVA desensitization using mycophenolate and low-dose prednisone treatment.
Nousari HC, Anhalt GJ, Morison WL. Mycophenolate in Psoralen–UV-A Desensitization Therapy for Chronic Actinic Dermatitis. Arch Dermatol. 1999;135(9):1128–1129. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-9-dlt0999
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: